José Gregorio Soto Campos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
José Gregorio Soto Campos has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Francisco Javier Álvarez-Gutiérrez
UMQER Asthma Unit, Virgen del Rocío University Hospital, Seville, Spain
6 shared publications Isabel Urrutia Landa
Respiratory Department, Galdakao Hospital, Galdakao, Bizkaia, Spain
4 shared publications- Vicente Plaza
Department of Respiratory Medicine and Allergy Barcelona Hospital de la Santa Creu i Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU)
4 shared publications Alicia Padilla Galo
Pneumology Service, Hospital Costa del Sol, Marbella, Málaga, Spain
3 shared publicationsAlicia Padilla-Galo
Servicio de Neumología, Hospital Universitario Virgen de la Victoria, Málaga, Spain
3 shared publicationsCarlos Almonacid Sánchez
Hospital Ramón y Cajal, Madrid, Madrid, Spain
3 shared publications
Latest Publications
- Open Access
- 2 September 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
The Global Airways Unit: A Multidisciplinary Strategy for Early Diagnosis and Comorbidity Detection
Background: Chronic respiratory diseases impose a large global burden of morbidity, mortality, and cost. The concept of a global airway has become increasingly supported by epidemiologic, mechanistic, and clinical evidence. However, clinical care often remains fragmented between ear, nose, and throat (ENT), allergy, and pulmonology. Methods: A multidisciplinary expert panel composed of allergists, pulmonologists, and otolaryngologists from multiple tertiary care centres was convened. Experts were selected using predefined criteria encompassing clinical experience, academic output, geographic and institutional diversity, and gender balance. The panel performed a structured synthesis of current international guidelines and high‐impact literature, using a modified Delphi consensus process over 3 rounds, with a predefined agreement threshold of ≥ 80% to define the scope of diseases, diagnostic approach, and interdisciplinary care model. Results: The Global Airways Unit (GAU) framework prioritizes multidisciplinary teamwork, early detection of comorbidities, phenotype‑directed investigations, streamlined imaging, and assignment of a lead specialty with scheduled follow‑up. Expected benefits include earlier diagnosis, improved disease control and quality of life (QoL), reduced duplication of testing, and potential cost‑savings for patients and health systems. Conclusions: The GAU operationalises the unified airway hypothesis into a reproducible clinical model. We propose the formation of a GAU to coordinate the management of patients with inflammatory airway diseases. Prospective real‑world evaluation of GAU implementation is the next critical step to validate clinical and economic outcomes.
- 2 September 2026
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
Open AccessThe Global Airways Unit: A Multidisciplinary Strategy for Early Diagnosis and Comorbidity Detection
Background: Chronic respiratory diseases impose a large global burden of morbidity, mortality, and cost. The concept of a global airway has become increasingly supported by epidemiologic, mechanistic, and clinical evidence. However, clinical care often remains fragmented between ear, nose, and throat (ENT), allergy, and pulmonology. Methods: A multidisciplinary expert panel composed of allergists, pulmonologists, and otolaryngologists from multiple tertiary care centres was convened. Experts were selected using predefined criteria encompassing clinical experience, academic output, geographic and institutional diversity, and gender balance. The panel performed a structured synthesis of current international guidelines and high‐impact literature, using a modified Delphi consensus process over 3 rounds, with a predefined agreement threshold of ≥ 80% to define the scope of diseases, diagnostic approach, and interdisciplinary care model. Results: The Global Airways Unit (GAU) framework prioritizes multidisciplinary teamwork, early detection of comorbidities, phenotype‑directed investigations, streamlined imaging, and assignment of a lead specialty with scheduled follow‑up. Expected benefits include earlier diagnosis, improved disease control and quality of life (QoL), reduced duplication of testing, and potential cost‑savings for patients and health systems. Conclusions: The GAU operationalises the unified airway hypothesis into a reproducible clinical model. We propose the formation of a GAU to coordinate the management of patients with inflammatory airway diseases. Prospective real‑world evaluation of GAU implementation is the next critical step to validate clinical and economic outcomes.
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (12) , 1689-1700
Eosinophilic inflammation in severe asthma: Pathophysiology, clinical identification, and therapeutic implications
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- Vol. 63 (12) , 1689-1700
Eosinophilic inflammation in severe asthma: Pathophysiology, clinical identification, and therapeutic implications
A critical step in the management of uncontrolled severe asthma—estimated to affect 3–4% of asthma patients (1)—is the identification of the inflammatory phenotype. Severe asthma is a heterogeneous...
- Open Access
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1785849
Expert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and heterogeneous immune-mediated disorder in which eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. In clinical practice, diagnosis remains challenging because no single biomarker reliably captures disease complexity, and therapeutic decisions must still be based on careful integration of clinical, laboratory, imaging, and histopathological findings. In recent years, EGPA management has evolved from a largely glucocorticoid-based approach toward a more phenotype-oriented strategy that distinguishes eosinophilic and vasculitic manifestations and incorporates targeted biologic therapies. This Perspective discusses current challenges and emerging opportunities in EGPA diagnosis and treatment, with emphasis on early recognition, multidisciplinary assessment, glucocorticoid-sparing strategies, and individualized long-term follow-up. Specific recommendations are provided on diagnostic orientation, phenotype-driven therapeutic selection, and the practical use of conventional immunosuppressants and anti–IL-5/IL-5R biologics according to disease severity and organ involvement. In addition, we propose a new treatment algorithm intended to support real-world decision-making and to facilitate a more consistent and structured approach to care. By combining expert recommendations with a forward-looking perspective on evolving therapeutic strategies, this article aims to contribute to safer, more effective, and more personalized management of patients with EGPA.
- 13 April 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1785849
Open AccessExpert review and recommendations on the diagnosis and therapeutic management of eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and heterogeneous immune-mediated disorder in which eosinophilic inflammation, vasculitis, and airway disease coexist in highly variable combinations. In clinical practice, diagnosis remains challenging because no single biomarker reliably captures disease complexity, and therapeutic decisions must still be based on careful integration of clinical, laboratory, imaging, and histopathological findings. In recent years, EGPA management has evolved from a largely glucocorticoid-based approach toward a more phenotype-oriented strategy that distinguishes eosinophilic and vasculitic manifestations and incorporates targeted biologic therapies. This Perspective discusses current challenges and emerging opportunities in EGPA diagnosis and treatment, with emphasis on early recognition, multidisciplinary assessment, glucocorticoid-sparing strategies, and individualized long-term follow-up. Specific recommendations are provided on diagnostic orientation, phenotype-driven therapeutic selection, and the practical use of conventional immunosuppressants and anti–IL-5/IL-5R biologics according to disease severity and organ involvement. In addition, we propose a new treatment algorithm intended to support real-world decision-making and to facilitate a more consistent and structured approach to care. By combining expert recommendations with a forward-looking perspective on evolving therapeutic strategies, this article aims to contribute to safer, more effective, and more personalized management of patients with EGPA.
- Open Access
- 25 February 2026
- Published by Elsevier in Open Respiratory Archives
- Vol. 8 (2) , 100603
Prevalence of Asthma and Associated Comorbidities in the Spanish Population: A Cross-sectional Survey
- 25 February 2026
- Published by Elsevier in Open Respiratory Archives
- Vol. 8 (2) , 100603
Open AccessPrevalence of Asthma and Associated Comorbidities in the Spanish Population: A Cross-sectional Survey
- Open Access
- 1 December 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (4) , 385-422
Consenso ALAT-SEPAR sobre la definición y clasificación de las exacerbaciones del asma según su gravedad: hacia una estandarización internacional
Asthma exacerbation is a significant clinical event that occurs with varying severity, yet a set of universally accepted standardized definitions is still needed. The aim of this consensus developed by ALAT and SEPAR was to fill this gap with a validated proposal for classifying asthma exacerbations into levels of severity: non-severe, severe, and very severe. The consensus was based on an in-depth review of the literature conducted by the scientific committee to identify key parameters for each level of severity, including worsening symptoms, respiratory function changes, and the need for specific medical interventions. A total of 67 publications were analyzed to generate a questionnaire on the defining elements of asthma exacerbations, and this was put to the vote. Twenty-eight international experts participated in the validation of characteristics and definitions of exacerbation severity following Delphi methodology. The resulting definitions clearly distinguish non-severe exacerbations (requiring minor adjustments in treatment) from severe exacerbations (requiring more intensive interventions, including longer systemic corticosteroid use or hospitalization) and very severe exacerbations (life-threatening events requiring intensive care). These definitions provide a standardized framework that facilitates comparison between clinical trials and optimizes patient care. This consensus lays the foundation for unifying management criteria in global clinical practice and fostering research on the efficacy of asthma treatments. It also underlines the importance of accurate classification in improving clinical outcomes and reducing the overall burden of disease.
- 1 December 2025
- Published by Asociacion Latinoamericana de Torax in Respirar
- Vol. 17 (4) , 385-422
Open AccessConsenso ALAT-SEPAR sobre la definición y clasificación de las exacerbaciones del asma según su gravedad: hacia una estandarización internacional
Asthma exacerbation is a significant clinical event that occurs with varying severity, yet a set of universally accepted standardized definitions is still needed. The aim of this consensus developed by ALAT and SEPAR was to fill this gap with a validated proposal for classifying asthma exacerbations into levels of severity: non-severe, severe, and very severe. The consensus was based on an in-depth review of the literature conducted by the scientific committee to identify key parameters for each level of severity, including worsening symptoms, respiratory function changes, and the need for specific medical interventions. A total of 67 publications were analyzed to generate a questionnaire on the defining elements of asthma exacerbations, and this was put to the vote. Twenty-eight international experts participated in the validation of characteristics and definitions of exacerbation severity following Delphi methodology. The resulting definitions clearly distinguish non-severe exacerbations (requiring minor adjustments in treatment) from severe exacerbations (requiring more intensive interventions, including longer systemic corticosteroid use or hospitalization) and very severe exacerbations (life-threatening events requiring intensive care). These definitions provide a standardized framework that facilitates comparison between clinical trials and optimizes patient care. This consensus lays the foundation for unifying management criteria in global clinical practice and fostering research on the efficacy of asthma treatments. It also underlines the importance of accurate classification in improving clinical outcomes and reducing the overall burden of disease.
- Open Access
- 6 November 2025
- Published by Elsevier in Open Respiratory Archives
- Vol. 7 (4)
ALAT-SEPAR Consensus on the Definition and Classification of Asthma Exacerbations by Severity: A Move Toward International Standardization
- 6 November 2025
- Published by Elsevier in Open Respiratory Archives
- Vol. 7 (4)
Open AccessALAT-SEPAR Consensus on the Definition and Classification of Asthma Exacerbations by Severity: A Move Toward International Standardization
- Open Access
- 13 May 2025
- Published by Elsevier in Open Respiratory Archives
- Vol. 7 (3) , 100442
Expert Consensus on Single-Inhaler Triple Therapy for the Treatment of Asthma in Adult Patients
- 13 May 2025
- Published by Elsevier in Open Respiratory Archives
- Vol. 7 (3) , 100442
Open AccessExpert Consensus on Single-Inhaler Triple Therapy for the Treatment of Asthma in Adult Patients
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 17, 1163-1171
Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
Purpose: With the advent of biological therapies, emerging concepts regarding establishing new targets in asthma management, such as disease modification, have entered the debate among the scientific community. The definitions that form the conceptual basis of this goal need to be agreed upon. Methods: A multidisciplinary expert group was assembled as the steering committee. A systematic literature review was conducted to identify the scientific background for constructing appropriate definitions. Based on the literature review and the clinical experience of the experts, the committee built a list of statements that could be applied to establish the definition of disease modification in asthma. After that, a Delphi validation was performed to assess the appropriateness of the list of statements. The questionnaire included a total of 22 statements, divided into “Essential criteria for disease modification in asthma” (5 statements) and “Disease modification indicators and other considerations” (17 statements). Panelists used a 9-point Likert scale to measure agreement on each statement. The cut-off point for high consensus was defined as a minimum score of 7 and had to be reached by at least two-thirds of the experts. Results: A total of 192 asthma experts voted on statements anonymously. Of those, 104 (54%) were Pneumologists, 65 (34%) were allergologists, and 23 (12%) were Pediatricians. An interim analysis of round 1 data was performed. All statements reached consensus on the first round, with a median score above 7 in all cases. Conclusion: In conclusion, in this Delphi study, a large number of experts in the management of severe asthma from different specialties agreed on the clinical-functional and pathophysiological aspects to be considered in order to try to achieve disease modification.
- 1 November 2024
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 17, 1163-1171
Open AccessDisease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
Purpose: With the advent of biological therapies, emerging concepts regarding establishing new targets in asthma management, such as disease modification, have entered the debate among the scientific community. The definitions that form the conceptual basis of this goal need to be agreed upon. Methods: A multidisciplinary expert group was assembled as the steering committee. A systematic literature review was conducted to identify the scientific background for constructing appropriate definitions. Based on the literature review and the clinical experience of the experts, the committee built a list of statements that could be applied to establish the definition of disease modification in asthma. After that, a Delphi validation was performed to assess the appropriateness of the list of statements. The questionnaire included a total of 22 statements, divided into “Essential criteria for disease modification in asthma” (5 statements) and “Disease modification indicators and other considerations” (17 statements). Panelists used a 9-point Likert scale to measure agreement on each statement. The cut-off point for high consensus was defined as a minimum score of 7 and had to be reached by at least two-thirds of the experts. Results: A total of 192 asthma experts voted on statements anonymously. Of those, 104 (54%) were Pneumologists, 65 (34%) were allergologists, and 23 (12%) were Pediatricians. An interim analysis of round 1 data was performed. All statements reached consensus on the first round, with a median score above 7 in all cases. Conclusion: In conclusion, in this Delphi study, a large number of experts in the management of severe asthma from different specialties agreed on the clinical-functional and pathophysiological aspects to be considered in order to try to achieve disease modification.
- Open Access
- 1 January 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 79-88
Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
Background: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. Objective: The aim of the present study was to evaluate the effectiveness of add-on reslizumab in a cohort of patients with SEUA under real-life conditions. Methods: This was a multi-centre, retrospective, real-life study that included subjects with SEUA treated with reslizumab in 44 asthma units throughout Spain. Eligible patients were those who had received at least one dose of reslizumab as part of normal clinical practice. The primary endpoint was complete asthma control at 52 weeks, defined as absence of severe exacerbations, ACT ≥ 20 and no maintenance oral corticosteroids (OCS). Demographic, clinical, and functional data were collected at baseline (T0), after four to six months (T1); after 12 months (T2) and beyond 12 months of therapy (T3). Results: Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0– 4.0 at V0 to 0.0; IQR: 0.0– 0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0– 61.6 at T0 to 18.5% (95% CI: 12.5– 24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p < 0.001). Most of the improvement achieved at 12 months was obtained at 4– 6 months. The retention (continuation) rate of reslizumab was 75% through 2 years (95CI%: 1.9– 2.1). Overall, reslizumab showed an adequate safety profile. Conclusion: Reslizumab is an effective therapy for SEUA with adequate safety profile in real-life conditions.
- 1 January 2022
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 15, 79-88
Open AccessAsthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data
Background: Reslizumab is an anti-interleukin 5 monoclonal antibody that has demonstrated to reduce the risk of severe exacerbations and to improve symptoms, lung function, and quality of life in randomized controlled trials that included patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. Objective: The aim of the present study was to evaluate the effectiveness of add-on reslizumab in a cohort of patients with SEUA under real-life conditions. Methods: This was a multi-centre, retrospective, real-life study that included subjects with SEUA treated with reslizumab in 44 asthma units throughout Spain. Eligible patients were those who had received at least one dose of reslizumab as part of normal clinical practice. The primary endpoint was complete asthma control at 52 weeks, defined as absence of severe exacerbations, ACT ≥ 20 and no maintenance oral corticosteroids (OCS). Demographic, clinical, and functional data were collected at baseline (T0), after four to six months (T1); after 12 months (T2) and beyond 12 months of therapy (T3). Results: Treatment with reslizumab achieved complete asthma control in 40% of the 208 included SEUA patients and led to a significant reduction in exacerbations (from 3.0; IQR: 2.0– 4.0 at V0 to 0.0; IQR: 0.0– 0.0 at V2), maintenance OCS use (from 54.8% (95% CI: 48.0– 61.6 at T0 to 18.5% (95% CI: 12.5– 24.5 at T2) and a meaningful improvement in symptoms in the entire treated population: ACT increased from 12.8 ± 4.5 at V0 to 20.0 ± 5.1 at V2 (p < 0.001). Most of the improvement achieved at 12 months was obtained at 4– 6 months. The retention (continuation) rate of reslizumab was 75% through 2 years (95CI%: 1.9– 2.1). Overall, reslizumab showed an adequate safety profile. Conclusion: Reslizumab is an effective therapy for SEUA with adequate safety profile in real-life conditions.